The ECHELON-2 Trial: Results of a Randomized, Double-Blind, Active-Controlled Phase 3 Study of Brentuximab Vedotin and CHP (A plus CHP) Versus CHOP in the Frontline Treatment of Patients with CD30+Peripheral T-Cell Lymphomas

被引：2

作者：

Horwitz, Steven M. ^{[1
]}

O'Connor, Owen A. ^{[2
]}

Pro, Barbara ^{[3
]}

Illidge, Tim M. ^{[4
]}

Fanale, Michelle A. ^{[5
]}

Advani, Ranjana H. ^{[6
]}

Bartlett, Nancy L. ^{[7
]}

Christensen, Jacob Haaber ^{[8
]}

Morschhauser, Franck ^{[9
]}

Domingo-Domenech, Eva ^{[10
]}

Rossi, Giuseppe ^{[11
]}

Kim, Won Seog ^{[12
]}

Feldman, Tatyana A. ^{[13
]}

Lennard, Anne ^{[14
]}

Belada, David ^{[15
,16
]}

Illes, Arpad ^{[17
]}

Tobinai, Kensei ^{[18
]}

Tsukasaki, Kunihiro ^{[19
]}

Yeh, Su-Peng ^{[20
]}

Shustov, Andrei R. ^{[21
]}

Huettmann, Andreas ^{[22
]}

Savage, Kerry J. ^{[23
,24
]}

Yuen, Sam ^{[25
]}

Zinzani, Pier Luigi ^{[26
]}

Hua, Zhaowei ^{[27
]}

Little, Meredith ^{[27
]}

Rao, Shangbang ^{[28
]}

Woolery, Joseph ^{[28
]}

Manley, Thomas ^{[29
]}

Truemper, Lorenz ^{[30
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Basking Ridge, NJ USA

[2] Columbia Univ, Med Ctr, New York, NY USA

[3] Northwestern Univ, Dept Med, Feinberg Sch Med, Div Hematol & Oncol, Chicago, IL 60611 USA

[4] Univ Manchester, Christie Hosp NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Div Canc Sci,Fac Biol Med & Hlth,NIHR Biomed Res, Manchester, Lancs, England

[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[6] Stanford Canc Ctr, Blood & Marrow Transplant Program, Stanford, CA USA

[7] Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO USA

[8] Odense Univ Hosp, Odense, Denmark

[9] CHRU Lille, Lille, Nord Pas De Cal, France

[10] Inst Catala Oncol, Barcelona, Spain

[11] Azienda Osped Spedali Civili Brescia, Brescia, Italy

[12] Samsung Med Ctr, Seoul, South Korea

[13] Hackensack Univ Med Ctr, Hackensack, NJ USA

[14] Freeman Rd Hosp, Newcastle Upon Tyne, Tyne & Wear, England

[15] Univ Hosp, Dept Internal Med Hematol 4, Hradec Kralove, Czech Republic

[16] Charles Univ Prague, Fac Med, Prague, Czech Republic

[17] Debreceni Egyet, Debrecen, Hungary

[18] Natl Canc Ctr, Tokyo, Japan

[19] Saitama Med Univ, Dept Hematol, Int Med Ctr, Saitama, Japan

[20] China Med Univ Hosp, Taichung, Taiwan

[21] Univ Washington, Med Ctr, Seattle, WA 98195 USA

[22] Univ Klinikum Essen, Essen, Germany

[23] Univ British Columbia, Vancouver, BC, Canada

[24] British Columbia Canc Agcy, Ctr Lymphoid Canc, Dept Med Oncol, Vancouver, BC, Canada

[25] Calvary Mater Newcastle Hosp, Newcastle, NSW, Australia

[26] Univ Bologna, Inst Hematol Seragnoli, Bologna, Italy

[27] Takeda Pharmaceut Int Co, Cambridge, MA USA

[28] Seattle Genet, Bothell, WA USA

[29] Seattle Genet Inc, Bothell, WA USA

[30] Univ Med Gottingen, Gottingen, Germany

来源：

BLOOD | 2018年 / 132卷

关键词：

D O I：

10.1182/blood-2018-99-110563

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

997

引用

页数：5

共 50 条

[1] The ECHELON-2 Trial: Results of a Randomized, Double-Blind, Active-Controlled Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients With CD30+ Peripheral T-Cell Lymphomas
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (02) : 8 - 10
[2] The ECHELON-2 trial: Results of a randomised, double-blind, active-controlled phase 3 study of brentuximab vedotin and CHP (A plus CHP) vs CHOP in the frontline treatment of patients (pts) with CD30+ peripheral T-cell lymphomas (PTCLs)
Truemper, L.
O'Connor, O. A.
Pro, B.
Illidge, T. M.
Advani, R. H.
Bartlett, N. L.
Christensen, Haaber J.
Morschhauser, F.
Domingo-Domenech, E.
Rossi, G.
Kim, W. S.
Feldman, T. A.
Lennard, A.
Belada, D.
Illes, A.
Tobinai, K.
Tsukasaki, K.
Yeh, S. -P.
Shustov, A. R.
Huettmann, A.
Savage, K. J.
Yuen, S.
Iyer, S.
Zinzani, P. L.
Hua, Z.
Little, M.
Rao, S.
Woolery, J.
Manley, T.
Horwitz, S. M.
ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 23 - 23
[3] The ECHELON-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A plus CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma
Iyer, Swaminathan
Truemper, Lorenz
O'Connor, Owen A.
Pro, Barbara
Illidge, Tim
Advani, Ranjana
Bartlett, Nancy L.
Christensen, Jacob Haaber
Morschhauser, Franck
Domingo-Domenech, Eva
Rossi, Giuseppe
Kim, Won Seog
Feldman, Tatyana
Menne, Tobias
Belada, David
Illes, Arpad
Tobinai, Kensei
Tsukasaki, Kunihiro
Yeh, Su-Peng
Shustov, Andrei
Huettmann, Andreas
Savage, Kerry J.
Yuen, Sam
Zinzani, Pier Luigi
Miao, Harry
Bunn, Veronica
Fenton, Keenan
Fanale, Michelle
Puhlmann, Markus
Horwitz, Steven
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S411 - S411
[4] The Echelon-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A plus CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma
Horwitz, Steven M.
O'Connor, Owen A.
Pro, Barbara
Illidge, Tim
Iyer, Swami P.
Advani, Ranjana
Bartlett, Nancy L.
Christensen, Jacob Haaber
Morschhauser, Franck
Domingo-Domenech, Eva
Rossi, Giuseppe
Kim, Won Seog
Feldman, Tatyana A.
Menne, Tobias
Belada, David
Illes, Arpad
Tobinai, Kensei
Tsukasaki, Kunihiro
Yeh, Su-Peng
Shustov, Andrei R.
Huttmann, Andreas
Savage, Kerry J.
Yuen, Sam
Zinzani, Pier Luigi
Miao, Harry
Bunn, Veronica
Fenton, Keenan
Fanale, Michelle A.
Puhlmann, Markus
Truemper, Lorenz
BLOOD, 2020, 136
[5] An Exploratory Analysis of Brentuximab Vedotin Plus CHP (A plus CHP) in the Frontline Treatment of Patients with CD30+Peripheral T-Cell Lymphomas (ECHELON-2): Impact of Consolidative Stem Cell Transplant
Savage, Kerry J.
Horwitz, Steven M.
Advani, Ranjana H.
Christensen, Jacob H.
Domingo-Domenech, Eva
Rossi, Giuseppe
Morschhauser, Franck
Alpdogan, Onder
Suh, Cheolwon
Tobinai, Kensei
Shustov, Andrei R.
Trneny, Marek
Yuen, Sam
Zinzani, Pier Luigi
Truemper, Lorenz
Illidge, Timothy
O'Connor, Owen
Pro, Barbara
Little, Meredith
Bunn, Veronica
Fenton, Keenan
Manley, Thomas
Iyer, Swaminathan P.
BLOOD, 2019, 134
[6] Exploratory analysis of retreatment with brentuximab vedotin (BV) after frontline treatment with brentuximab vedotin and CHP (A plus CHP) for patients (pts) with CD30+peripheral T-cell lymphoma (ECHELON-2)
Truemper, L.
Pro, B.
Horwitz, S.
O'connor, O.
Tilly, H.
Choi, I.
Gritti, G.
Fox, C.
Alpdogan, O.
Mayer, J.
Briones, J.
Jacobsen, E.
Pezzutto, A.
Demeter, J.
Gurion, R.
Jurczak, W.
Kuo, C. -Y.
Opat, S.
Little, M.
Brown, L.
Puhlmann, M.
Illidge, T.
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 119 - 119
[7] The Echelon-2 Trial: 5-Year Exploratory Subgroup Analyses of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A plus CHP) Vs CHOP in Frontline Treatment of Pts with CD30-Positive Peripheral T-Cell Lymphoma
Horwitz, Steven M.
Savage, Kerry J.
Timillidge
Plyer, Swaminathan
Advani, Ranjana
Shustov, Andrei R.
Bartlett, Nancy L.
Pro, Barbara
Jacobsen, Eric D.
Koch, Raphael
Eva, Domingo Domenech
Fanale, Michelle A.
Fenton, Keenan
Campana, Frank
Dong, Cassie
Truemper, Lorenz
BLOOD, 2021, 138
[8] Exploratory Analysis of Brentuximab Vedotin Plus CHP (A plus CHP) as Frontline Treatment for Patients with CD30-Expressing PERIPHERAL T-Cell Lymphomas (Echelon-2): Impact of Consolidative Stem Cell Transplant
Trneny, Marek
Savage, Kerry J.
Horwitz, Steven M.
Advani, Ranjana
Christensen, Jacob H.
Domingo-Domenech, Eva
Rossi, Giuseppe
Morschhauser, Franck
Alpdogan, Onder
Suh, Cheolwon
Tobinai, Kensei
Shustov, Andrei R.
Yuen, Sam
Zinzani, Pier Luigi
Trumper, Lorenz
Illidge, Timothy
O'Connor, Owen
Pro, Barbara
Little, Meredith
Bunn, Veronica
Fenton, Keenan
Manley, Thomas
Iyer, Swaminathan P.
BONE MARROW TRANSPLANTATION, 2020, 55 (SUPPL 1) : 115 - 116
[9] ECHELON-2, (NCT01777152), 5-year results of a randomised, double-blind, phase 3 study of frontline brentuximab vedotin plus CHP vs CHOP in patients with CD30-positive peripheral T-cell lyphoma
Truemper, L.
O'Connor, O. A.
Pro, B.
Illidge, T.
Advani, R.
Bartlett, N. L.
Christensen, J. H.
Morschhauser, F.
Domingo-Domenech, E.
Rossi, G.
Kim, W. S.
Feldman, T.
Menne, T.
Belada, D.
Illes, A.
Tobinai, K.
Tsukasaki, K.
Yeh, S. P.
Huettmann, A.
Savage, K. J.
Yuen, S.
Iyer, S.
Zinzani, P. L.
Miao, H.
Bunn, V
Fenton, K.
Fanale, M.
Puhlmann, M.
Horwitz, S.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 128 - 128
[10] PHASE 3 TRIAL OF BRENTUXIMAB VEDOTIN AND CHP VERSUS CHOP IN THE FRONTLINE TREATMENT OF PATIENTS (PTS) WITH CD30+MATURE T-CELL LYMPHOMAS (MTCL)
Illidge, T.
Pro, B.
Truemper, L. H.
Larsen, E. K.
Huebner, D.
Kennedy, D. A.
O'Connor, O.
ANNALS OF ONCOLOGY, 2014, 25

← 1 2 3 4 5 →